Wall Street brokerages expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to report earnings of ($0.82) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Alpine Immune Sciences’ earnings, with the lowest EPS estimate coming in at ($0.96) and the highest estimate coming in at ($0.63). Alpine Immune Sciences posted earnings of ($0.33) per share in the same quarter last year, which indicates a negative year over year growth rate of 148.5%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 27th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.62) per share for the current financial year, with EPS estimates ranging from ($2.79) to ($2.46). For the next financial year, analysts forecast that the firm will report earnings of ($2.84) per share, with EPS estimates ranging from ($3.26) to ($2.11). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 43.25% and a negative net margin of 1,602.19%.
A number of brokerages recently weighed in on ALPN. ValuEngine raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, November 27th. Finally, Oppenheimer set a $13.00 price target on shares of Alpine Immune Sciences and gave the stock a “buy” rating in a report on Monday, November 12th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Alpine Immune Sciences currently has an average rating of “Buy” and a consensus target price of $11.83.
In other Alpine Immune Sciences news, Director James N. Topper acquired 372,439 shares of Alpine Immune Sciences stock in a transaction dated Friday, January 18th. The stock was purchased at an average cost of $5.37 per share, for a total transaction of $1,999,997.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mitchell Gold acquired 190,875 shares of Alpine Immune Sciences stock in a transaction dated Friday, January 18th. The shares were acquired at an average price of $5.37 per share, with a total value of $1,024,998.75. The disclosure for this purchase can be found here. 69.00% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its holdings in Alpine Immune Sciences by 109.0% during the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares during the last quarter. Hikari Power Ltd purchased a new position in Alpine Immune Sciences during the fourth quarter worth about $453,000. Vanguard Group Inc boosted its holdings in Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Alpine Immune Sciences by 20.9% during the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 21,124 shares during the last quarter. Institutional investors and hedge funds own 55.63% of the company’s stock.
NASDAQ ALPN traded down $0.98 during mid-day trading on Tuesday, reaching $5.50. 64,550 shares of the stock were exchanged, compared to its average volume of 15,320. Alpine Immune Sciences has a one year low of $3.66 and a one year high of $10.57. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.20 and a quick ratio of 9.20.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Recommended Story: Understanding each part of a balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.